On April 28, 2018 Ipsen (Euronext: IPN; ADR: IPSEY) reported that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC) (Press release, Ipsen, MAR 28, 2018, View Source [SID1234525464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The filing is based on the results of the global placebo-controlled phase 3 CELESTIAL trial which met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant improvement and clinically meaningful improvement in median OS compared with placebo in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib.

Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen, said:

"This milestone is an important step forward for the cabozantinib ongoing development program
across solid tumors, with the potential, if approved, to provide patients with advanced HCC – which is still an unmet medical need – with a new oral systemic treatment."